Commercial ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option BioPharma DiveAt a big meeting for weight loss drugs, Lilly s triple G therapy set a new standard as lingering doubts surrounded other competing treatments.Metabolic & GLP-1Read full story pharminent June 8, 2026 (Last updated: June 8, 2026) BioPharma Dive At a big meeting for weight loss drugs, Lilly s triple G therapy set a new standard as lingering doubts surrounded other competing treatments. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reductionNext: J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B Related Stories Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026
